Wolfgang Baiker MD, PhD – Most recently Dr. Wolfgang Baiker was interim CEO at Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. In his preceding position, Dr. Baiker served as President and CEO Boehringer Ingelheim USA since January 2018. His prior key positions included Member of the Board of Managing Directors with global responsibility for Production, Quality and the Biopharmaceutics Business Unit, Global Head of Development and Global Head of Project Management. He holds a Doctorate in Medicine from the University of Ulm (Germany) and an MBA from Pace University, New York (USA).
Jennifer Hartt, BS, MS – Jennifer Hartt, is the past Managing Director, Healthcare Investment Group at Ben Franklin. Hartt directed all of Ben Franklin’s life sciences related investments in companies with technologies ranging from clinical healthcare IT, medical devices and diagnostics to therapeutics. Jenn has closed over 150 investments totaling some $45M in over 80 companies since early 2006.Jenn has prior experience in lab research, clinical settings, and business consulting for small and large companies, technology evaluation and transfer, licensing and equity management. Jenn holds a Master’s in Biology (with a focus on molecular biology and genetics) and Bachelor’s degree in Biology, graduating summa cum laude and Phi Beta Kappa, with both degrees from the University of Pennsylvania.
Robert Alonso, Founder & CEO – has 25 years of experience with both large pharmaceutical companies (Merck, Roche) and small biotech companies (Ceptaris). Most recently Mr Alonso successfully founded Ceptaris Therapeutics, where he raised over $40 million in venture capital, steered the lead program through phase III testing and filing of an NDA (Approval was received in 2013). Ceptaris was sold in 2013 to Actellion Pharmaceuticals. Mr. Alonso is a seasoned executive who has completed numerous licensing and other business transactions, including raising venture capital and negotiating transactions worth over $500 million. He has brought several drugs through the Investigational New Drug (IND) process and one through a successful completion of a New Drug Application (NDA). Mr. Alonso is the inventor on 9 issued patents. Mr Alonso has a BS from Boston College and MBA in Entrepreneurship from Babson College.
John G. Geisler, PhD, Founder & Chief Scientific Officer – Dr. Geisler comes with 25+ years of research experience with a consistent pharmacological focus of trying to work at the root of problems; 15-years focused on metabolic drug discovery for Pfizer, Ionis, and Johnson & Johnson Pharmaceutical Research and Development (J&J PRD). Dr. Geisler has expertise in mitochondrial energy expenditure from years of attempting to partition lipids to restore insulin sensitivity and reduce the comorbidities associated with the “over-nutritional phenotype” (Geisler, J.G. Diabetologia 2011). From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders and neurodegenerative diseases. Dr. Geisler is the author of over 50 papers & abstracts, and the co-inventor on a number of patents. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), with a dissertation on the characterization of a novel muscle protein with dystrophin-like characteristics. His fellowship at Yale University, focused on the protective effects of E2 related to diabetic sexual dimorphism, by studying islet biology, physiology and whole-body flux.